Am J Surg

1. HANUSCHAK D, DePiero M, DeMoraes M, Bailly S, et al
   The impact of COVID-19 on patients diagnosed with melanoma, breast, and colorectal cancer.
   Am J Surg. 2023 Sep 29:S0002-9610(23)00496-8. doi: 10.1016/j.amjsurg.2023.
   

   >> Share

   
   

   
   Ann Surg Oncol

2. CHUNG A
   ASO Author Reflections: Considerations in the Debate on Sentinel Node Biopsy in Older Patients with ER+/Her2- Breast Cancer.
   Ann Surg Oncol. 2024 Feb 21. doi: 10.1245/s10434-024-15095.
   

   >> Share

   
   
3. BARKER VR, Naffouje SA, Mallory MA, Hoover SA, et al
   ASO Visual Abstract: Surgical Management of the Axilla in HR+/HER2-Breast Cancer in the Z1071 Era: A Propensity-Score Matched Analysis of the National Cancer Database.
   Ann Surg Oncol. 2024 Feb 19. doi: 10.1245/s10434-024-15063.
   

   >> Share

   
   
4. CHUN JW, Kang E, Kim HK, Lee HB, et al
   Oncological Safety of Skipping Axillary Lymph Node Dissection in Patients with Clinical N0, Sentinel Node-Positive Breast Cancer Undergoing Total Mastectomy.
   Ann Surg Oncol. 2024 Feb 17. doi: 10.1245/s10434-024-15049.
   

   >> Share

   
   
5. LAWS A, Leonard S, Hershey E, Stokes S, et al
   ASO Visual Abstract: Upgrade Rates and Breast Cancer Development Among Germline Pathogenic Variant Carriers with High-Risk Breast Lesions.
   Ann Surg Oncol. 2024 Feb 16. doi: 10.1245/s10434-024-15067.
   

   >> Share

   
   

   
   BMC Cancer

6. ABEDI M, Sahebi L, Eslami B, Saberi A, et al
   Using a combination of superb microvascular imaging and other auxiliary ultrasound techniques to increase the accuracy of gray-scale ultrasound for breast masses.
   BMC Cancer. 2024;24:224.
   

   >> Share

   
   
7. BEN-ZION BERLINER M, Yust-Katz S, Lavie I, Goldberg Y, et al
   Central nervous system metastases in breast cancer patients with germline BRCA pathogenic variants compared to non-carriers: a matched-pair analysis.
   BMC Cancer. 2024;24:219.
   

   >> Share

   
   

   
   Br J Cancer

8. YU T, Yang C, Li M
   Comment on "Pathological complete response, category change, and prognostic significance of HER2-low breast cancer receiving neoadjuvant treatment: a multicenter analysis of 2489 cases".
   Br J Cancer. 2024 Feb 20. doi: 10.1038/s41416-024-02616.
   

   >> Share

   
   

   
   Breast Cancer

9. KIM N, Cho WK, Park W, Lee JE, et al
   Outcomes of whole breast radiation therapy in Asian breast cancer patients with prior cosmetic implants.
   Breast Cancer. 2024 Feb 18. doi: 10.1007/s12282-024-01547.
   

   >> Share

   
   

   
   Breast Cancer (Auckl)

10. KHALID IB, Sarwar A, Khalid HB, Sajjad B, et al
    Clinicopathological Features and Treatment Outcomes of Male Breast Cancer in Pakistani Population: A 10-Year Retrospective Cross-Sectional Study.
    Breast Cancer (Auckl). 2024;18:11782234241233120.
    

    >> Share

    
    

    
    Breast Cancer Res

11. HEESCH A, Florea A, Maurer J, Habib P, et al
    The prostate-specific membrane antigen holds potential as a vascular target for endogenous radiotherapy with [(177)Lu]Lu-PSMA-I&T for triple-negative breast cancer.
    Breast Cancer Res. 2024;26:30.
    

    >> Share

    
    
12. DEROUANE F, Desgres M, Moroni C, Ambroise J, et al
    Metabolic adaptation towards glycolysis supports resistance to neoadjuvant chemotherapy in early triple negative breast cancers.
    Breast Cancer Res. 2024;26:29.
    

    >> Share

    
    
13. SCHEFFGES C, Devy J, Giustiniani J, Francois S, et al
    Identification of CD160-TM as a tumor target on triple negative breast cancers: possible therapeutic applications.
    Breast Cancer Res. 2024;26:28.
    

    >> Share

    
    

    
    Breast Cancer Res Treat

14. CHEN Y, Markowitz JC, Blanco C, Hershman DL, et al
    Geographical distance predicts psychiatric treatment retention for Hispanic women with comorbid major depression and breast cancer.
    Breast Cancer Res Treat. 2024 Feb 20. doi: 10.1007/s10549-024-07250.
    

    >> Share

    
    
15. BUFMAN H, Faermann R, Halshtok-Neiman O, Shalmon A, et al
    Breast cancer diagnosed after age 70 years in Israeli BRCA1/BRCA2 pathogenic sequence variant carriers: a single institution experience.
    Breast Cancer Res Treat. 2024 Feb 21. doi: 10.1007/s10549-023-07234.
    

    >> Share

    
    
16. GEURTS SME, Ibragimova KIE, Ding N, Meegdes M, et al
    Time trends in real-world treatment patterns and survival in patients diagnosed with de novo HER2+ metastatic breast cancer: an analysis of the SONABRE registry.
    Breast Cancer Res Treat. 2024 Feb 21. doi: 10.1007/s10549-023-07235.
    

    >> Share

    
    
17. FALEH S, Prakash I, Salehi A, Khan H, et al
    Preoperative factors that predict pathologic nodal involvement in early-stage HER2+ breast cancer: selecting cT1cN0 patients for treatment with neoadjuvant chemotherapy versus upfront surgery.
    Breast Cancer Res Treat. 2024 Feb 21. doi: 10.1007/s10549-024-07251.
    

    >> Share

    
    

    
    Cancer Lett

18. MURTHY D, Dutta D, Attri KS, Samanta T, et al
    CD24 negativity reprograms mitochondrial metabolism to PPARalpha and NF-kappaB-driven fatty acid beta-oxidation in triple-negative breast cancer.
    Cancer Lett. 2024 Feb 17:216724. doi: 10.1016/j.canlet.2024.216724.
    

    >> Share

    
    

    
    Cancer Res

19. YAMAMOTO T, Hayashida T, Masugi Y, Oshikawa K, et al
    PRMT1 sustains de novo fatty acid synthesis by methylating PHGDH to drive chemoresistance in triple-negative breast cancer.
    Cancer Res. 2024 Feb 22. doi: 10.1158/0008-5472.CAN-23-2266.
    

    >> Share

    
    

    
    Clin Breast Cancer

20. ZHU Z, Wang H, Qian X, Xue M, et al
    Inhibitory Impact Of Cinobufagin In Triple-Negative Breast Cancer Metastasis: Involvements Of Macrophage Reprogramming Through Upregulated MME and Inactivated FAK/STAT3 Signaling.
    Clin Breast Cancer. 2024 Jan 26:S1526-8209(24)00025.
    

    >> Share

    
    
21. LIU D, Chang L, Zhao X, Dai L, et al
    Effect of T Stages on the Choice of Axillary Evaluation Modality in Breast Cancer Patients With 1-2 Sentinel Lymph Node Metastases.
    Clin Breast Cancer. 2024 Jan 24:S1526-8209(24)00022.
    

    >> Share

    
    

    
    Clin Cancer Res

22. GUARDUCCI C, Nardone A, Russo D, Nagy Z, et al
    Selective CDK7 inhibition suppresses cell cycle progression and MYC signaling while enhancing apoptosis in therapy-resistant estrogen receptor positive breast cancer.
    Clin Cancer Res. 2024 Feb 21. doi: 10.1158/1078-0432.CCR-23-2975.
    

    >> Share

    
    
23. MAMOUNAS EP, Bandos H, Rastogi P, Zhang Y, et al
    Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial.
    Clin Cancer Res. 2024 Feb 20. doi: 10.1158/1078-0432.CCR-23-1977.
    

    >> Share

    
    

    
    Clin Exp Metastasis

24. POURJAMAL N, Yazdi N, Halme A, Joncour VL, et al
    Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model.
    Clin Exp Metastasis. 2024 Feb 17. doi: 10.1007/s10585-024-10278.
    

    >> Share

    
    

    
    Clin Med Insights Oncol

25. ABULKHAIR O, Omair A, Makanjuola D, Al Zaid M, et al
    Breast Cancer in Young Women: Is It Different? A Single-Center Retrospective Cohort Study.
    Clin Med Insights Oncol. 2024;18:11795549241228235.
    

    >> Share

    
    

    
    Eur J Cancer

26. TARANTINO P, Ajari O, Graham N, Vincuilla J, et al
    Evolution of HER2 expression between pre-treatment biopsy and residual disease after neoadjuvant therapy for breast cancer.
    Eur J Cancer. 2024;201:113920.
    

    >> Share

    
    

    
    Eur Radiol

27. JING X, Dorrius MD, Zheng S, Wielema M, et al
    Localization of contrast-enhanced breast lesions in ultrafast screening MRI using deep convolutional neural networks.
    Eur Radiol. 2024;34:2084-2092.
    

    >> Share

    
    
28. LOKAJ B, Pugliese MT, Kinkel K, Lovis C, et al
    Barriers and facilitators of artificial intelligence conception and implementation for breast imaging diagnosis in clinical practice: a scoping review.
    Eur Radiol. 2024;34:2096-2109.
    

    >> Share

    
    
29. SEKER ME, Koyluoglu YO, Ozaydin AN, Gurdal SO, et al
    Diagnostic capabilities of artificial intelligence as an additional reader in a breast cancer screening program.
    Eur Radiol. 2024 Feb 22. doi: 10.1007/s00330-024-10661.
    

    >> Share

    
    

    
    Int J Radiat Oncol Biol Phys

30. CACHO-DIAZ B, Tripathy D, Arrieta VA, Escamilla-Ramirez A, et al
    Real-world experience in Hispanic Patients with Breast Cancer and Brain Metastases using different Prognostic Tools.
    Int J Radiat Oncol Biol Phys. 2024 Feb 14:S0360-3016(24)00305.
    

    >> Share

    
    

    
    J Clin Oncol

31. SHAH M, Lingam H, Gao X, Gittleman H, et al
    US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer.
    J Clin Oncol. 2024 Feb 21:JCO2302112. doi: 10.1200/JCO.23.02112.
    

    >> Share

    
    

    
    J Natl Cancer Inst

32. XIAO Q, Mao X, Ploner A, Grassmann F, et al
    Cancer risks among first-degree relatives of women with a genetic predisposition to breast cancer.
    J Natl Cancer Inst. 2024 Feb 14:djae030. doi: 10.1093.
    

    >> Share

    
    

    
    J Surg Oncol

33. KIM M, Carter J, Tadros AB, Abuhdra N, et al
    A guide for addressing sexual health in breast cancer patients.
    J Surg Oncol. 2024 Feb 22. doi: 10.1002/jso.27602.
    

    >> Share

    
    

    
    Mod Pathol

34. AL ASSAAD M, Michaud O, Semaan A, Sigouros M, et al
    Whole-Genome Sequencing Analysis of Male Breast Cancer Unveils Novel Structural Events and Potential Therapeutic Targets.
    Mod Pathol. 2024 Feb 16:100452. doi: 10.1016/j.modpat.2024.100452.
    

    >> Share

    
    

    
    NPJ Breast Cancer

35. MENG P, Dalal H, Chen Y, Brueffer C, et al
    Digital PCR quantification of ultrahigh ERBB2 copy number identifies poor breast cancer survival after trastuzumab.
    NPJ Breast Cancer. 2024;10:14.
    

    >> Share

    
    
36. CHAUDHARY N, Chibly AM, Collier A, Martinalbo J, et al
    CDK4/6i-treated HR+/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape.
    NPJ Breast Cancer. 2024;10:15.
    

    >> Share

    
    

    
    Oncogene

37. REID SE, Pantaleo J, Bolivar P, Bocci M, et al
    Cancer-associated fibroblasts rewire the estrogen receptor response in luminal breast cancer, enabling estrogen independence.
    Oncogene. 2024 Feb 22. doi: 10.1038/s41388-024-02973.
    

    >> Share

    
    
38. LIANG Y, Chen B, Xu F, Long L, et al
    LncRNA PRBC induces autophagy to promote breast cancer progression through modulating PABPC1-mediated mRNA stabilization.
    Oncogene. 2024 Feb 16. doi: 10.1038/s41388-024-02971.
    

    >> Share

    
    

    
    Pathology

39. KRYSTEL-WHITTEMORE M, Tan PH, Wen HY
    Predictive and prognostic biomarkers in breast tumours.
    Pathology. 2024;56:186-191.
    

    >> Share

    
    

    
    PLoS Genet

40. SCOTT TG, Sathyan KM, Gioeli D, Guertin MJ, et al
    TRPS1 modulates chromatin accessibility to regulate estrogen receptor alpha (ER) binding and ER target gene expression in luminal breast cancer cells.
    PLoS Genet. 2024;20:e1011159.
    

    >> Share

    
    

    
    Proc Natl Acad Sci U S A

41. LAUBLI H
    Unraveling the impact of a glyco-immune checkpoint in bone metastasis.
    Proc Natl Acad Sci U S A. 2024;121:e2400499121.
    

    >> Share

    
    

    
    Radiol Imaging Cancer

42. FIELDS BKK, Joe BN
    Screening Breast MRI Effectively Detects Early-Stage Breast Cancer in High-Risk Patients without Prior History of Breast Cancer.
    Radiol Imaging Cancer. 2024;6:e249005.
    

    >> Share

    
    

    
    Radiology

43. MONTICCIOLO DL, Hendrick RE, Helvie MA
    Outcomes of Breast Cancer Screening Strategies Based on Cancer Intervention and Surveillance Modeling Network Estimates.
    Radiology. 2024;310:e232658.
    

    >> Share

    
    

    
    Radiother Oncol

44. WHELAN TJ, Fyles A, Parpia S, Nielsen T, et al
    LUMINA: Using molecular biomarkers to guide decision making for breast radiotherapy.
    Radiother Oncol. 2024;190:110074.
    

    >> Share

    
    
45. WINTRAECKEN VM, Boersma LJ, van Roozendaal LM, de Vries J, et al
    Quality assurance of radiation therapy after breast-conserving surgery among patients in the BOOG 2013-08 trial.
    Radiother Oncol. 2024;191:110069.
    

    >> Share

    
    
46. OLLONI A, Lorenzen EL, Jeppesen SS, Diederichsen A, et al
    An open source auto-segmentation algorithm for delineating heart and substructures - Development and validation within a multicenter lung cancer cohort.
    Radiother Oncol. 2024;191:110065.
    

    >> Share

    
    
47. MEATTINI I, Marta GN, Carroll S, Rivera S, et al
    Omission of radiation therapy after breast-conserving surgery for biologically favourable tumours in younger patients: The wrong answer to the right question.
    Radiother Oncol. 2024;190:110045.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share